Viatris Inc., founded on November 16, 2020, is a global healthcare company headquartered in Canonsburg, Pennsylvania. Formed through the merger of Mylan and Upjohn, Viatris aims to empower people worldwide to live healthier lives at every stage. The company produces a wide range of pharmaceuticals, including generic drugs, biosimilars, and active pharmaceutical ingredients, targeting both noncommunicable and infectious diseases. With a mission to provide access to high-quality medicines, Viatris serves clients across the globe.
Notable figures associated with Viatris include CEO Scott A. Smith. The company is publicly traded on Nasdaq under the ticker VTRS and is a component of the S&P 500. In 2023, Viatris reported revenues of $15.39 billion and a net income of $54.7 million. Its significant achievements include a robust portfolio that addresses diverse therapeutic areas and a strong global presence, making a substantial impact on global healthcare accessibility and innovation.
